“Bimekizumab Rates of Oral Candidiasis in Patients With Moderate to Severe Plaque Psoriasis: Results from up to 4 Years of Five Phase 3 3b Studies”. 2025. SKIN The Journal of Cutaneous Medicine 9 (6): s646. https://doi.org/10.25251/ta5v8k92.